双肼酞嗪 | 484-23-1

• 物质功能分类: 原料药 - 循环系统用药 - 抗高血压病药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 双肼酞嗪
• 中文别名: 血压达静；双肼屈嗪；双肼苯哒嗪
• 英文名称: 1,4-bis(hydrazino)phthalazine
• 英文别名: dihydralazin；dihydralazine；(4-hydrazinylphthalazin-1-yl)hydrazine
• CAS: 484-23-1
• 化学式: C₈H₁₀N₆
• mdl: MFCD01250766
• 分子量: 190.208
• InChiKey: VQKLRVZQQYVIJW-UHFFFAOYSA-N

物化性质

• 熔点：
  180°C (rough estimate)
• 沸点：
  315.71°C (rough estimate)
• 密度：
  1.3243 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  102
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090

制备方法与用途

化学性质

橙色针状结晶。约在180℃分解。一般临床应用的为硫酸盐，即C8H10N6·H2SO4（[2740-03-6]），呈现白色针状结晶，熔点为233℃（开始分解），略溶于沸水，微溶于水或乙醇。

用途

该物质是一种降压药，可以直接作用于周围血管以降低血压。在降压的同时，还能增加心、脑、肾和内脏的血流量，并促进肾素分泌及水钠潴留。通常与其他药物联合使用治疗各类高血压。由于其显著降低舒张压以及增加血流的效果，特别适用于肾功能不全和舒张压高的患者，且极少引起直立性低血压。此外，它还可用于含羰基高分子化合物的交联剂、络合剂，并在分析化学领域有所应用。

生产方法

由二氯酞嗪（[4752-10-7]）经过醚化和肼化反应制得。

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	1-chloro-4-hydrazinophthalazine	59275-72-8	C8H7ClN4	194.623

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	1,4-diethyl phthalazinylhydrazocarboxylate	239077-04-4	C14H18N6O4	334.335
  ——	1-N,4-N-bis(cinnamylideneamino)phthalazine-1,4-diamine	27702-33-6	C26H22N6	418.501
  ——	1-N,4-N-bis[(E)-[(E)-3-phenylprop-2-enylidene]amino]phthalazine-1,4-diamine	27702-33-6	C26H22N6	418.5
  ——	1-N,4-N-bis[(4-fluorophenyl)methylideneamino]phthalazine-1,4-diamine	——	C22H16F2N6	402.406
  ——	1-N,4-N-bis[(4-chlorophenyl)methylideneamino]phthalazine-1,4-diamine	27702-20-1	C22H16Cl2N6	435.315
  ——	1,4-Bis(2-(4-chlorobenzylidene)hydrazinyl)phthalazine	27702-20-1	C22H16Cl2N6	435.3
  ——	1-N,4-N-bis[[4-(dimethylamino)phenyl]methylideneamino]phthalazine-1,4-diamine	27704-14-9	C26H28N8	452.562
  ——	bis(salicylaldehyde)-1,4-dihydrazinophtalazine	27703-96-4	C22H18N6O2	398.424
  ——	bis(2-chlorobenzaldehyde)-1,4-dihydrazinophtalazine	27702-18-7	C22H16Cl2N6	435.315
  ——	1,4-Bis{[(3,4-dichlorophenyl)methylidene]hydrazinylidene}-1,2,3,4-tetrahydrophthalazine	27702-23-4	C22H14Cl4N6	504.205

反应信息

• 作为反应物：
  描述：

  双肼酞嗪 在 sodium hydroxide 、 氧气 作用下， 以 乙醇 为溶剂， 反应 2.5h， 以68%的产率得到2,3-二氮杂萘
  参考文献：
  名称：

  Streptonigrin. 1. Structure-activity relationships among simple bicyclic analogs. Rate dependence of DNA degradation on quinone reduction potential

  摘要：

  A series of simple aza and diaza bicyclic quinones related to the AB ring system of streptonigrin (1) have been synthesized and tested in vitro for their ability to degrade DNA under conditions similar to those used with the parent drug. The results obtained from a study of 22 quinones indicate that there is a quantitative linear relationship between their reduction potentials and the rate at which they degrade DNA under identical conditions in vitro. Almost all of the synthetic substances were superior to 1 in their DNA-degrading ability.

  DOI：

  10.1021/jm00158a002
• 作为产物：
  描述：

  1-chloro-4-hydrazinophthalazine 在 一水合肼 作用下， 生成 双肼酞嗪
  参考文献：
  名称：

  DE847748

  摘要：

  公开号：

文献信息

• FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20170275282A1

  公开（公告）日：2017-09-28

  The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

  这项发明涉及取代的吡啶苯并脑和吡啶苯并哌啶衍生物，以及其制备方法，还涉及将其用于生产用于治疗和/或预防疾病的药物，特别是心血管疾病，最好是血栓性或血栓栓塞性疾病，水肿，以及眼科疾病。
• [EN] SUBSTITUTED OXOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXOPYRIDINE SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2017005725A1

  公开（公告）日：2017-01-12

  The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and o edemas, and also ophthalmic disorders.

  这项发明涉及替代氧吡啶衍生物及其制备方法，以及它们用于制备治疗和/或预防疾病的药物，特别是心血管疾病，最好是血栓性或血栓栓塞性疾病，以及水肿和眼科疾病。
• SUBSTITUTED BIPIPERIDINYL DERIVATIVES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20160318866A1

  公开（公告）日：2016-11-03

  The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  该发明涉及新型取代的双哌啶衍生物，涉及它们的制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡，特别是促进糖尿病足溃疡愈合、糖尿病心力衰竭、糖尿病冠状微血管心脏疾病、外周和心脏血管疾病、血栓栓塞疾病和缺血、外周循环障碍、雷诺现象、CREST综合征、微循环障碍、间歇性跛行以及外周和自主神经病变的治疗和/或预防。
• SUBSTITUTED BENZOXAZOLES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160108027A1

  公开（公告）日：2016-04-21

  The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders.

  本发明涉及取代苯并恶唑及其制备方法，以及它们用于制备治疗和/或预防疾病，特别是心血管疾病，尤其是血栓性或血栓性栓塞疾病的药物的应用。
• [EN] BINDING-SITE MODIFIED LECTINS AND USES THEREOF<br/>[FR] LECTINES DE SITE DE LIAISON MODIFIÉES ET USAGE CORRESPONDANT
  申请人：SMARTCELLS INC

  公开号：WO2010088261A1

  公开（公告）日：2010-08-05

  In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one covalently linked affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.

  在一个方面，该公开提供了包括多价凝集素的交联材料，其中该多价凝集素具有至少两个葡萄糖结合位点，其中该凝集素包括至少一个与亲和配体共价连接的亲和配体，该亲和配体能够与至少一个所述结合位点中的葡萄糖竞争结合；以及包括绑定到共轭框架的两个或更多个独立亲和配体的共轭物，其中这两个或更多个亲和配体与葡萄糖在所述结合位点上与凝集素竞争结合，其中由于不同共轭物上的凝集素和亲和配体之间的非共价相互作用，共轭物在材料内交联。这些材料旨在根据所需葡萄糖浓度释放共轭物的量。根据最终应用，在各种实施例中，共轭物还可以包括药物和/或可检测标记。